You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨君實生物逆勢升超4%,治療肝癌藥上市申請獲受理
君實生物(1877.HK)逆勢升4.59%報13.22港元,A股逆勢升2%報32.5元。消息面上,公司昨晚公佈,收到國家藥品監督管理局有關特瑞普利單抗,商品名拓益,聯合貝伐珠單抗一線治療晚期肝細胞癌的新適應症上市申請,已經獲得受理。公司指,該新適應症上市申請主要基於HEPATORCH研究,研究結果顯示,相較於索拉非尼,可顯著延長患者的無進展生存期和總生存期,同時改善客觀緩解率和至疾病進展時間等次要終點。特瑞普利單抗安全性數據與已知風險相符,未發現新的安全性訊號,而有關研究的詳細數據將在後續的國際學術大會上公佈。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account